within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BD01_CoagulationFactorIxIiViiAndXInCombination;
model CoagulationFactorIxIiViiAndXInCombination 
   extends Pharmacolibrary.Drugs.ATC.B.B02BD01;

  annotation(Documentation(
    info ="<html><body><p>This combination is a prothrombin complex concentrate (PCC), comprised of human blood plasma-derived coagulation factors II, VII, IX, and X, typically used for the treatment and prevention of bleeding in patients with deficiency of multiple vitamin K-dependent clotting factors, such as in cases of warfarin reversal or hereditary deficiency. Prothrombin complex concentrates are still approved and in clinical use, such as in urgent reversal of anticoagulation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are variably reported for individual factors, but specific PK for the 4-factor PCC combination limited. Data below are representative values estimated for adult populations from published summaries and product monographs.</p><h4>References</h4><ol><li><p>Honickel, M, et al., &amp; Grottke, O (2016). Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model. <i>Thrombosis and haemostasis</i> 115(2) 271â€“284. DOI:<a href=&quot;https://doi.org/10.1160/TH15-03-0266&quot;>10.1160/TH15-03-0266</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26333775/&quot;>https://pubmed.ncbi.nlm.nih.gov/26333775</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end CoagulationFactorIxIiViiAndXInCombination;
